|
|
Article: KOSAN STOPS NSCLC PHASE II BUT 'UPBEAT' ON EPOTHILONES.
- Article from:
- BIOWORLD Today
- Article date:
- November 24, 2004
- Author:
CopyrightCOPYRIGHT 2004 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Randall Osborne, West Coast Editor
The same cancer drug from Kosan Biosciences Inc. that met with combination-toxicity problems in a study against colorectal tumors has failed to meet its primary objective in a Phase II study against non-small-cell lung cancer, and the company is stopping that trial, as well.
"If we knew why certain drugs in certain tumors fail, we'd all be billionaires," said Robert Johnson, chief medical officer of Hayward, Calif.-based Kosan, adding that the firm is "pretty upbeat" about ongoing efforts to develop the compound known as KOS-862.
Kosan's stock (NASDAQ:KOSN) closed Tuesday at $6.40, down 15 ...